246 related articles for article (PubMed ID: 20406176)
21. Trial watch: Lung cancer trial aims to bolster personalized medicine.
Harrison C
Nat Rev Drug Discov; 2014 Jun; 13(6):407. PubMed ID: 24875087
[No Abstract] [Full Text] [Related]
22. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
23. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations.
Ferrer F; Fanciullino R; Milano G; Ciccolini J
Clin Pharmacol Ther; 2020 Sep; 108(3):458-470. PubMed ID: 32557660
[TBL] [Abstract][Full Text] [Related]
24. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine.
Groenland SL; Mathijssen RHJ; Beijnen JH; Huitema ADR; Steeghs N
Eur J Clin Pharmacol; 2019 Sep; 75(9):1309-1318. PubMed ID: 31175385
[TBL] [Abstract][Full Text] [Related]
25. Personalized medicine and economic evaluation in oncology: all theory and no practice?
Garattini L; Curto A; Freemantle N
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):733-8. PubMed ID: 26289733
[TBL] [Abstract][Full Text] [Related]
26. Personalized medicine in oncology: the future is now.
Schilsky RL
Nat Rev Drug Discov; 2010 May; 9(5):363-6. PubMed ID: 20431568
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
[TBL] [Abstract][Full Text] [Related]
28. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
29. Strategies to optimize the use of targeted agents for tumor therapy.
Becker JC; Ugurel S; Schrama D
J Dtsch Dermatol Ges; 2008 Apr; 6(4):281-5. PubMed ID: 18205839
[TBL] [Abstract][Full Text] [Related]
30. Computational oncology--mathematical modelling of drug regimens for precision medicine.
Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
[TBL] [Abstract][Full Text] [Related]
31. Targeted cancer therapy--are the days of systemic chemotherapy numbered?
Joo WD; Visintin I; Mor G
Maturitas; 2013 Dec; 76(4):308-14. PubMed ID: 24128673
[TBL] [Abstract][Full Text] [Related]
32. The rocky road to personalized medicine in acute myeloid leukaemia.
Brinda B; Khan I; Parkin B; Konig H
J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
[TBL] [Abstract][Full Text] [Related]
33. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapies for small cell lung cancer: Where do we stand?
Arcaro A
Crit Rev Oncol Hematol; 2015 Aug; 95(2):154-64. PubMed ID: 25800975
[TBL] [Abstract][Full Text] [Related]
35. Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.
Porta C; Toscani I; Czarnecka AM; Szczylik CA
Expert Opin Biol Ther; 2017 Feb; 17(2):151-162. PubMed ID: 27960591
[TBL] [Abstract][Full Text] [Related]
36. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
37. The Role of Clinical Pharmacology in Oncology Dose Selection: Advances and Opportunities in Personalized Medicine.
Shord SS
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S99-S104. PubMed ID: 28921640
[No Abstract] [Full Text] [Related]
38. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
Yamazaki S; Spilker ME; Vicini P
Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
[TBL] [Abstract][Full Text] [Related]
39. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.
Liu S; Nikanjam M; Kurzrock R
Oncotarget; 2016 Mar; 7(10):11310-20. PubMed ID: 26824502
[TBL] [Abstract][Full Text] [Related]
40. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]